转移性结直肠癌的第三线治疗模式和临床结果:一项回顾性现实研究

Ting Deng1, Jingjing Duan2, Ming Bai2

  • 1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huanhu West Road, Tianjin 300060, China.

概括

在转移性结直肠癌 (mCRC) 中,用向药物的化疗是首选的第三线疗法,显示出比抗血管原性单一疗法更好的结果. 综合治疗策略可以提高患者的生存率.